索拉非尼

肾细胞癌靶向治疗进展&索拉非尼

Targeted drugs in the treatment of renal cell carcinoma : sorafenib

索拉非尼的药理及临床研究

Sorafenib : pharmacology and clinical studies

根据计划，当中期分析显示索拉非尼的效果明显优于安慰剂时，研究会过早的中止。

The study was stopped prematurely when a planned interim analysis showed sorafenib 's significant superiority over placebo .

我们希望索拉非尼能够成为患有这种致命疾病的病人的一个新的极其重要的治疗选择。

We hope to establish Nexavar as an important new treatment option for patients with this devastating disease .

当前索拉非尼在美国和其他国家被批准用来治疗晚期肾细胞癌。

Sorafenib is currently approved in the United States and other countries for treatment of advanced renal cell carcinoma .

据拜耳消息，研究人员和投资方目前正在对索拉非尼应用于各种乳腺癌治疗情况进行评测。

Investigators and cooperative groups are currently evaluating sorafenib in various breast cancer treatment settings , according to Bayer .

目前，我们正在进行一项多中心临床试验，研究在辅助治疗方案中添加索拉非尼是否有效。

We are currently doing a multi-centre trial looking to see if the addition of sorafenib in adjuvant therapy will be beneficial .